Study of Tepotinib and Ivonescimab for Non-Small Cell Lung Cancer
This study is looking into whether a combination of two drugs, tepotinib and ivonescimab, is a safe and effective treatment for people with non-small cell lung cancer (NSCLC). You may be able to join if your cancer has a specific change called MET exon 14 skipping. Researchers will test different doses of tepotinib to find the best dose that causes the fewest or mildest side effects when given with ivonescimab. The main goal is to find this best dose. This study plans to enroll 16 participants, but its current status is unclear.
- Study design
- This is an interventional study that plans to enroll 16 participants. It is testing different doses of tepotinib in combination with ivonescimab.
- What's involved
- Tepotinib is taken by mouth daily in 3-week cycles. Ivonescimab is given through an IV every 3 weeks on Day 1 of each cycle, for up to 24 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, dose finding, will be measured at 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
7 sites across 2 statesStudy leadership
- Paul Paik, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Dose finding2 years
The primary objective of the dose finding phase is determination of the recommended dose expansion dose using a standard 3+3 design based on dose-limiting toxicities (DLT). DLT definition: any grade ≥ 3 immune-related adverse event attributable to synergistic combinatorial toxicity from tepotinib and ivonescimab.